EXOME Analysis Position in the Strategy of Genetic Predisposition Factors Identification in Early-onset Cancer (EX²TRICAN)

  • End date
    Oct 10, 2024
  • participants needed
  • sponsor
    Centre Georges Francois Leclerc
Updated on 15 February 2022
breast cancer
primary cancer


5 to 10% of cancers are due to the presence of a constitutional genetic alteration. It can be inherited from parents (family form) or by accident, in the first moments of life after fertilization (sporadic form). In both cases, this genetic alteration is constitutional and transmissible to descendants. It is hereditary. When an hereditary early form is suspected, several well-known genes generally involved in genetic predispositions to cancer are found by a technique called " gene panel ". However, this analysis does not always identify the genetic predisposing factors for cancer. New techniques called "high-throughput exome sequencing (SHD-E)", allow more than the analysis of the the gene panel. These analysis allow to identify alterations in other genes that could contribute to the development of cancer. The objective of the Extrican study is to show, from patients with early cancer (sporadic or familial form), that this approach to exome sequencing can be effective to identify new genetic risk of cancer, when the first panel analysis of genes is negative.


The main objective of this study is to evaluate the interest of the SHD-E approaches after a negative result of the analysis called " gene panel " tested in routine in order to identify a genetic factor of predisposition to the cancer.

Condition Cancer, Genetic Predisposition
Treatment Blood sample
Clinical Study IdentifierNCT04141462
SponsorCentre Georges Francois Leclerc
Last Modified on15 February 2022


Yes No Not Sure

Inclusion Criteria

Index case
Major or minor patient
Histological or cytological evidence of malignant tumor diagnosis
Patient with cancer before age 40 (or before age 30 for breast cancer)
Absence of anomaly found on the oncogenetic panel tested in the predisposition concerned
Patient affiliated to a social security scheme
Signature of Informed Consent EXTRICAN
Availability of a tumor sample if needed secondary functional studies
Availability of both parents when the trio approach will be necessary in the population 1 (or validation of the indication in CPR in case of non-availability of both parents)
Availability of affected relatives in population 2 (or validation of the indication in SPC in case of non-availability of the related person)
Major or minor patient
Histological or cytological evidence of the diagnosis of malignant tumor if
Patient affiliated to a social security scheme
Signing informed consent EXTRICAN

Exclusion Criteria

Index and related case
Refusal of the patient participation
Psychiatric illness and / or condition of the patient compromising the understanding of the information or the realization of the study
Patient under guardianship, curatorship or safeguard of justice
Pregnant woman
Clear my responses

How to participate?

Step 1 Connect with a study center
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact



Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider


Browse trials for

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 



Reply by • Private

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note